Sublicensing. 4.1 Upon written approval, which shall include prior review of any sublicense agreement by the IC and which shall not be unreasonably withheld, the Licensee may enter into sublicensing agreements under the Licensed Patent Rights.
Appears in 7 contracts
Samples: Patent License Agreement – Exclusive (CARGO Therapeutics, Inc.), Public Health Service (Atlantic Coastal Acquisition Corp. II), Public Health Service
Sublicensing. 4.1 Upon written approval, which shall include prior review of any sublicense agreement by the IC and which shall not be unreasonably withheld, the Licensee may enter into sublicensing agreements under the Licensed Patent Rights only when it concurrently licenses proprietary or in-licensed intellectual property rights. For the avoidance of doubt, the Licensee does not have the right to solely sublicense the Licensed Patent Rights.
Appears in 6 contracts
Samples: Patent License Agreement (PDS Biotechnology Corp), Patent License Agreement (Cellular Biomedicine Group, Inc.), Patent License Agreement (Cellular Biomedicine Group, Inc.)
Sublicensing. 4.1 Upon written approval, which shall include prior review of any sublicense agreement by the IC NIH and which shall not be unreasonably withheld, the Licensee may enter into sublicensing agreements under the Licensed Patent Rights.
Appears in 4 contracts
Samples: Patent License Agreement (Aura Biosciences, Inc.), Patent License Agreement (Aura Biosciences, Inc.), Health Patent License Agreement
Sublicensing. 4.1 Upon written approval, which shall include prior review of any sublicense agreement by the IC PHS and which shall not be unreasonably withheld, the Licensee may enter into sublicensing agreements under the Licensed Patent Rights.
Appears in 4 contracts
Samples: Patent License Agreement (Kinemed Inc), Patent License Agreement (Kinemed Inc), Patent License Agreement (Oculus Innovative Sciences, Inc.)
Sublicensing. 4.1 Upon written approval, which shall include prior review of any sublicense agreement by the IC NIH and which shall not be unreasonably withheldwithheld or delayed, the Licensee may enter into sublicensing agreements under the Licensed Patent Rights.
Appears in 2 contracts
Samples: Patent License Agreement (Lion Biotechnologies, Inc.), Patent License Agreement (Lion Biotechnologies, Inc.)
Sublicensing. 4.1 Upon written approval, which shall include prior review of any sublicense agreement by the IC and which shall not be unreasonably withheld, the Licensee may enter into sublicensing agreements under the Licensed Patent RightsRights during the term of any exclusive commercial license.
Appears in 1 contract
Samples: Patent License Agreement – Exclusive (CARGO Therapeutics, Inc.)
Sublicensing. 4.1 Upon written approval, which shall include prior review of any sublicense agreement by the IC [***] and which shall not be unreasonably withheld, the Licensee may enter into sublicensing agreements under the Licensed Patent Rights. With respect to any proposed sublicense agreement, if the IC does not provide the Licensee with written rejection thereof within [***], the IC shall be deemed to have given its approval of such sublicense agreement and the Licensee shall have the right to enter into such sublicense agreement.
Appears in 1 contract
Samples: Patent License Agreement Exclusive (Selecta Biosciences Inc)
Sublicensing. 4.1 Upon written approvalapproval by IC, which shall include prior review of any sublicense agreement by the IC and which shall not be unreasonably withheld, withheld the Licensee may enter into sublicensing agreements under the Licensed Patent RightsRights and the Orphan Drug Designation.
Appears in 1 contract
Samples: Patent License Agreement – Exclusive (Baudax Bio, Inc.)
Sublicensing. 4.1 Upon written approval, which shall include prior review of any sublicense agreement by the IC and which shall not be unreasonably withheld, the Licensee may enter into sublicensing agreements under the Licensed Patent RightsRights and the Orphan Drug Designation only when it concurrently licenses proprietary or in-licensed intellectual property rights. For the avoidance of doubt, the Licensee does not have the right to solely sublicense the Licensed Patent Rights or the Orphan Drug Designation.
Appears in 1 contract
Samples: Public Health Service (LogicBio Therapeutics, Inc.)
Sublicensing. 4.1 Upon 4.1Upon written approval, which shall include prior review of any sublicense agreement by the IC PHS and which shall not be unreasonably withheld, the . Licensee may enter into sublicensing agreements under the Licensed Patent Rights.
Appears in 1 contract
Sublicensing. 4.1 Upon written approval, which shall include prior review of any sublicense agreement by the IC and which shall not be unreasonably withheldwithheld or delayed, the Licensee may enter into sublicensing agreements under the Licensed Patent Rights.
Appears in 1 contract
Samples: Patent License Agreement ‒ Exclusive (Iovance Biotherapeutics, Inc.)
